Hermetica Superfood Encyclopedia
The Short Answer
Euphorbia hirta contains quercitrin, caffeic acid, and epicatechin 3-gallate as principal bioactive compounds that exert anti-inflammatory effects via COX-2 inhibition and antimicrobial effects by disrupting bacterial cell wall and cytoplasmic membrane integrity. A standardized methanolic extract designated PM 251 demonstrated significant COX-2 inhibitory activity in vitro, while caffeic acid and epicatechin 3-gallate showed antibacterial action against Pseudomonas aeruginosa with MIC values of 15.6 and 31.3 µg/mL, respectively, supporting its traditional role in treating respiratory infections.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordBagaruwar Masar Euphorbia hirta benefits
Bagaruwar Masar — botanical close-up
Health Benefits
**Respiratory and Bronchial Relief**
Quercitrin and rhamnetin contribute antispasmodic and anti-inflammatory effects on bronchial tissue, supporting the Hausa traditional use of this plant for asthma, coughs, and bronchial disorders through COX-2-mediated prostaglandin suppression.
**Antimicrobial Activity**
Caffeic acid and epicatechin 3-gallate disrupt both the cell wall and cytoplasmic membrane of Gram-negative pathogens such as Pseudomonas aeruginosa at MIC values of 15.6 and 31.3 µg/mL, providing a biochemical basis for its use in treating respiratory and wound infections.
**Anti-inflammatory Action**
A standardized methanol extract (PM 251) containing quercitrin, ferulic acid, gallic acid, and rhamnetin demonstrated significant COX-2 enzyme inhibition in vitro, reducing pro-inflammatory prostaglandin synthesis that underlies inflammation-driven respiratory and gastrointestinal conditions.
**Antioxidant Protection**
Phenolic acids including gallic acid and ferulic acid, along with flavonoids quercetin and myricitrin, scavenge reactive oxygen species, potentially protecting airway epithelial and hepatic cells from oxidative damage associated with infection and chronic disease.
**Potential Antiviral Properties**: Phytochemical constituents of E
hirta have demonstrated ACE inhibitory activity relevant to SARS-CoV-2 host cell entry blockade, and in silico studies identified compounds with potential inhibitory activity against the SARS-CoV-2 main protease (Mpro), though human clinical validation is absent.
**Gastrointestinal and Antidiarrheal Effects**
Tannins, saponins, and flavonoids in the plant exert astringent, antispasmodic, and antimicrobial actions on the gut mucosa, consistent with widespread traditional use across Africa and Asia for diarrhea and dysentery management.
**Wound Healing and Antimalarial Support**
Terpenoids including α-amyrin, β-amyrin, and taraxerone contribute to tissue repair and anti-inflammatory processes at wound sites, while documented antimalarial activity positions the plant as a broad-spectrum traditional remedy across its range of use.
Origin & History
Natural habitat
Euphorbia hirta is a small, annual hairy weed native to tropical America that has naturalized extensively throughout the tropics and subtropics of Africa, Asia, and the Pacific. In West Africa, it thrives in disturbed soils, roadsides, and cultivated fields across Nigeria, Ghana, and neighboring countries, where it is harvested wild rather than formally cultivated. In Hausa-speaking communities of northern Nigeria, the plant is commonly called Bagaruwar Masar and grows abundantly in and around settlements, making it accessible as a primary medicine for rural populations.
“Among Hausa communities in northern Nigeria and across the West African Sahel, Euphorbia hirta—called Bagaruwar Masar, meaning roughly 'Egyptian spurge' in Hausa—has been a cornerstone respiratory remedy, used to treat bronchial asthma, coughs, catarrh, and general respiratory infections for generations. Across sub-Saharan Africa, all parts of the plant are incorporated into traditional healing systems for wounds, boils, diarrhea, dysentery, and malaria, reflecting its broad pharmacological reputation and easy availability as a weed in human settlements. In the Philippines and across tropical Asia, the same plant is independently documented in folk medicine for respiratory disorders, laryngitis, and bronchitis, a remarkable convergence of traditional knowledge across geographically separated cultures that strengthens the ethnobotanical plausibility of its respiratory applications. Historical botanical surveys of tropical Africa and Asia from the 19th and early 20th centuries catalogued E. hirta as one of the most commonly used medicinal weeds, and it remains listed in numerous national pharmacopoeias and WHO documentation of traditional plant medicines across the tropics.”Traditional Medicine
Scientific Research
The evidence base for Euphorbia hirta consists predominantly of in vitro pharmacological screenings, GC-MS and HPLC phytochemical characterization studies, and in silico molecular docking investigations, with no published human randomized controlled trials identified in the available literature. In vitro studies have confirmed COX-2 inhibitory activity of the PM 251 methanolic extract and established MIC values for antibacterial constituents against P. aeruginosa, providing mechanistic plausibility but not clinical efficacy data. Computational studies examining potential SARS-CoV-2 Mpro inhibition by E. hirta phytochemicals represent early-stage exploratory research that has not yet advanced to cell-based or animal pharmacokinetic validation. The overall evidence profile is consistent with a Preliminary tier: the pharmacological activities are chemically grounded and the traditional use is ethnobotanically well-documented across multiple continents, but the absence of controlled human trials means clinical dose-response relationships, bioavailability, and comparative efficacy remain undefined.
Preparation & Dosage
Traditional preparation
**Traditional Aqueous Decoction (Hausa)**
Whole aerial parts or leaves are boiled in water for 15–30 minutes and consumed as a warm tea; no standardized dose has been established, but traditional use typically involves 1–2 cups daily for acute respiratory complaints.
**Methanolic/Ethanolic Extract (Research Grade)**
Standardized extracts such as PM 251 are prepared from aerial parts using methanol or ethanol; concentration is typically standardized to quercitrin content, though no commercially validated standardization percentage has been published.
**Aqueous Extract (Cold Infusion)**
Fresh or dried leaves are steeped in cold or warm water to preserve heat-labile compounds such as mucilage and certain glycosides; used across West African traditional practice for gastrointestinal applications.
**Topical Poultice**
Fresh crushed leaves or residue from decoctions are applied directly to wounds and boils in traditional African practice; no standardized preparation protocol has been defined.
**Hexane and Other Solvent Extracts (Laboratory)**
Hexane fractions isolate terpenoids and fatty acids including α-amyrin, β-amyrin, and palmitic acid; these are research tools rather than established supplement forms and are not recommended for lay use.
**Dosage Caution**
No evidence-based dosage range for human supplementation has been established; self-medication should be approached with caution and under guidance of a qualified practitioner familiar with West African herbal medicine.
Nutritional Profile
Euphorbia hirta is not consumed as a dietary food and therefore lacks a conventional macronutrient profile relevant to nutrition; its value lies entirely in its phytochemical content. Key bioactive phytochemicals include flavonoids (quercitrin, quercetin, rhamnetin, myricitrin), phenolic acids (gallic acid, ferulic acid, caffeic acid), and terpenoids (α-amyrin, β-amyrin, taraxerone, β-sitosterol), alongside tannins, saponins, alkaloids, cardiac glycosides, anthraquinones, coumarins, and mucilage. A methanolic extract GC-MS analysis identified palmitic acid (n-hexadecanoic acid) and nicotinic acid among thirty characterized compounds, and the amino acid derivative S-methyl-L-cysteine has also been isolated. Specific concentration percentages for individual phytochemicals have not been consistently published, and bioavailability data in humans—including absorption rates, first-pass metabolism, and tissue distribution of quercitrin or other key compounds—are not yet established in the scientific literature.
How It Works
Mechanism of Action
The primary anti-inflammatory mechanism operates through COX-2 enzyme inhibition by the flavonoid quercitrin and phenolic acids ferulic acid and gallic acid, collectively suppressing arachidonic acid conversion to pro-inflammatory prostaglandins and thromboxanes. Antimicrobial activity is mediated by caffeic acid and epicatechin 3-gallate, which target both the cell wall peptidoglycan layer and the cytoplasmic membrane of pathogens such as Pseudomonas aeruginosa, causing structural disruption and cell death at MIC concentrations of 15.6–31.3 µg/mL. Antiviral potential involves ACE inhibitory activity that may interfere with SARS-CoV-2 spike protein binding to ACE2 receptors on host cells, alongside in silico evidence that several phytoconstituents can dock into the active site of the SARS-CoV-2 main protease (Mpro), potentially blocking viral replication. Antioxidant mechanisms are driven by the polyphenol network—quercetin, myricitrin, gallic acid, and epicatechin 3-gallate—acting as electron donors to neutralize reactive oxygen species and chelate pro-oxidant metal ions, reducing oxidative stress in inflamed tissues.
Clinical Evidence
No human clinical trials with defined sample sizes, randomized designs, or quantified efficacy outcomes have been published for Euphorbia hirta as of the current literature review. The closest approximation to clinical evidence consists of in vitro studies demonstrating COX-2 inhibition and antibacterial MIC values, and in silico docking studies modeling antiviral binding interactions, none of which constitute clinical proof of efficacy in human subjects. Traditional ethnobotanical documentation across Hausa communities in Nigeria, Filipino folk medicine, and multiple African traditional medicine systems provides convergent observational evidence of respiratory, gastrointestinal, and wound-healing applications, but these accounts lack controlled conditions, standardized preparations, or outcome measurement. Confidence in clinical efficacy remains low by evidence-based medicine standards; the plant warrants properly designed Phase I and Phase II trials to establish safety, pharmacokinetics, and therapeutic dose ranges in humans.
Safety & Interactions
Formal toxicity studies and systematic adverse event data for Euphorbia hirta in humans are absent from the published literature, representing a significant safety evidence gap; the plant's widespread traditional use across multiple cultures over centuries suggests reasonable tolerability at typical decoction doses, but this does not constitute a validated safety assurance. The Euphorbia genus broadly contains diterpene esters (e.g., phorbol esters) with known irritant and tumor-promoting properties in some species, and while E. hirta's toxic potential appears lower than latex-rich relatives, dermal irritation from fresh latex and gastrointestinal upset from high doses are plausible concerns. Cardiac glycosides identified in the plant pose a theoretical interaction risk with digoxin and other cardiac glycoside medications, and the COX-2 inhibitory activity of flavonoid-rich extracts suggests potential additive effects with NSAIDs or anticoagulants such as warfarin. Pregnancy and lactation use is not recommended due to documented antifertility activity reported in traditional and pharmacological literature and the complete absence of reproductive safety data in humans.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Euphorbia hirtaAsthma weedBagaruwar MasarSnakeweedGarden spurgePillpod sandmatTawa-tawa (Philippines)
Frequently Asked Questions
What is Bagaruwar Masar used for in Hausa traditional medicine?
In Hausa communities of northern Nigeria, Bagaruwar Masar (Euphorbia hirta) is primarily used as a remedy for respiratory infections, bronchial asthma, coughs, and catarrh, typically prepared as a warm aqueous decoction of the aerial parts. The plant is also applied traditionally for wounds, boils, diarrhea, and dysentery, reflecting its broad antimicrobial and anti-inflammatory phytochemical profile including quercitrin, caffeic acid, and gallic acid.
What are the main active compounds in Euphorbia hirta?
The most pharmacologically significant compounds in Euphorbia hirta are the flavonoids quercitrin, quercetin, rhamnetin, and myricitrin, alongside phenolic acids including gallic acid, ferulic acid, and caffeic acid. Additional bioactives include the terpenoids α-amyrin, β-amyrin, and β-sitosterol, as well as epicatechin 3-gallate, tannins, saponins, and cardiac glycosides, with caffeic acid and epicatechin 3-gallate specifically demonstrating antibacterial activity at MIC values of 15.6 and 31.3 µg/mL against Pseudomonas aeruginosa.
Is Euphorbia hirta safe to use, and are there any drug interactions?
Human safety data for Euphorbia hirta is very limited, as no formal clinical toxicity or pharmacovigilance studies have been published; long-standing traditional use across Africa and Asia suggests general tolerability at typical decoction doses, but this is not a validated safety guarantee. The plant contains cardiac glycosides that may interact with digoxin and similar heart medications, and its COX-2 inhibitory flavonoids could produce additive effects with NSAIDs or anticoagulants like warfarin; use during pregnancy is not recommended due to reported antifertility properties.
Has Euphorbia hirta been studied for COVID-19 or antiviral activity?
Several in silico (computational) studies have investigated Euphorbia hirta phytochemicals for their potential to inhibit the SARS-CoV-2 main protease (Mpro) and ACE enzyme, which facilitates viral host cell entry, finding theoretical binding interactions with key compounds. However, these are early-stage computational models with no cell culture, animal, or human clinical trial validation, meaning the antiviral claims cannot be considered clinically proven and the plant should not be used as a COVID-19 treatment based on current evidence.
How is Euphorbia hirta prepared as a traditional medicine?
The most common traditional preparation across West Africa and Asia involves boiling the aerial parts—leaves, stems, and flowers—in water for 15–30 minutes to create a decoction consumed as a warm herbal tea, typically one to two cups daily for acute respiratory or gastrointestinal complaints. In some traditions, fresh crushed leaves are applied topically as a poultice for wounds and boils, while research laboratories use methanolic or ethanolic extraction to produce standardized extracts such as PM 251 for pharmacological investigation; no standardized commercial supplement form or validated human dosage protocol currently exists.
What is the most effective form of Euphorbia hirta for respiratory support—fresh plant, dried herb, or extract?
Dried herb preparations and standardized extracts of Euphorbia hirta are generally preferred for respiratory support because drying concentrates the active compounds like quercitrin and rhamnetin, while standardized extracts ensure consistent levels of these antispasmodic and anti-inflammatory constituents. Fresh plant material contains higher water content, which can dilute bioactive compounds, making dried decoctions or capsulized extracts more reliable for therapeutic effect. Traditional Hausa preparations typically use dried aerial parts steeped as tea, which balances efficacy with accessibility.
Does Euphorbia hirta interact with common asthma or bronchodilator medications?
Euphorbia hirta may have additive effects with asthma medications due to its antispasmodic properties and COX-2-mediated prostaglandin suppression, warranting caution when used alongside prescription bronchodilators or corticosteroids. While the herb's mechanism may theoretically complement certain respiratory treatments, concurrent use should be monitored by a healthcare provider to prevent over-relaxation of bronchial smooth muscle or unexpected potentiation. Individuals on regular asthma medication should consult their doctor before adding Euphorbia hirta as a therapeutic supplement.
Who is most likely to benefit from Euphorbia hirta supplementation for respiratory health?
Individuals with mild to moderate asthma, chronic cough, or bronchial inflammation may benefit most from Euphorbia hirta, particularly those seeking herbal alternatives or adjunctive support to conventional treatments. People with recurrent respiratory infections may also benefit from its antimicrobial activity via caffeic acid and epicatechin 3-gallate, which disrupt pathogenic cell walls and cytoplasmic membranes. However, those with severe asthma, immunocompromised status, or on multiple medications should consult a healthcare provider before use, as the herb's potency and interactions require professional oversight.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w bagaruwar-masar-euphorbia-hirta curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
